Difference between revisions of "Glucagon"
| Line 36: | Line 36: | ||
|- | |- | ||
| Surface accessibility | | Surface accessibility | ||
| − | | [http://gibk21.bse.kyutech.ac.jp/asaview/all/ | + | | [http://gibk21.bse.kyutech.ac.jp/asaview/all/1gcn.pdf ASAView] pdf |
| + | [http://gibk21.bse.kyutech.ac.jp/asaview/all/1gcn.txt ASAView] txt | ||
|- | |- | ||
| Disorder prediction | | Disorder prediction | ||
Revision as of 08:00, 25 July 2007
| Template:Infobox header| Glucagon | |
|---|---|
| Glucagon | |
| Substrate peptide name | Glucagon |
| Synonyms | - |
| Determination type | In vitro |
| Source | Homo sapiens |
| Subcellular localization | Extracellular; plasma |
| Swissprot ID | P01275 |
| Reactive glutamines | Q3, Q20 |
| Reactive lysines | - |
| Substrate sequence | HSQGTFTS
DSRRAQDFVQW |
| Structure | 1GCN |
| Surface accessibility | ASAView pdf
ASAView txt |
| Disorder prediction | IUPred |
| Reference | PMID:6101332 |
| Notes | |
| Template:Infobox header | | |
